Free Trial

Fulgent Genetics (FLGT) Stock Price, News & Analysis

Fulgent Genetics logo
$21.48 +0.18 (+0.85%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$21.43 -0.05 (-0.23%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Fulgent Genetics Stock (NASDAQ:FLGT)

Advanced

Key Stats

Today's Range
$21.07
▼
$21.64
50-Day Range
$16.55
▼
$22.36
52-Week Range
$13.46
▼
$31.04
Volume
297,613 shs
Average Volume
315,862 shs
Market Capitalization
$591.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.50
Consensus Rating
Hold

Company Overview

Fulgent Genetics, Inc. is a technology-driven clinical diagnostics company that provides genetic testing and laboratory services. The company uses next-generation sequencing and other molecular testing technologies to support the diagnosis, risk assessment and management of inherited diseases, cancer and other medical conditions.

Its offerings include hereditary disease testing, oncology testing, reproductive health testing and specialized genetic panels. Fulgent also provides laboratory-developed tests, pharmacogenetic testing and testing solutions for healthcare providers, hospitals, health systems, employers, pharmaceutical companies and public health organizations. The company previously provided large-scale COVID-19 testing services and has since focused on expanding its broader clinical diagnostics and precision medicine capabilities.

Fulgent Genetics was founded in 2011 and is headquartered in Temple City, California. Its services are primarily offered in the United States, with the company working with healthcare and institutional customers across multiple regions. Ming Hsieh, who founded the company, serves as its chairman and chief executive officer.

AI Generated. May Contain Errors.

Fulgent Genetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

FLGT MarketRank™: 

Fulgent Genetics scored higher than 69% of companies evaluated by MarketBeat, and ranked 212th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fulgent Genetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Fulgent Genetics has a consensus price target of $27.50, representing about 28.0% upside from its current price of $21.48.

  • Amount of Analyst Coverage

    Fulgent Genetics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Fulgent Genetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Fulgent Genetics are expected to grow in the coming year, from ($3.48) to ($2.76) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fulgent Genetics is -7.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fulgent Genetics is -7.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fulgent Genetics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Fulgent Genetics' valuation and earnings.
  • Percentage of Shares Shorted

    13.20% of the float of Fulgent Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulgent Genetics has a short interest ratio ("days to cover") of 6.71.
  • Change versus previous month

    Short interest in Fulgent Genetics has recently decreased by 2.12%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fulgent Genetics does not currently pay a dividend.

  • Dividend Growth

    Fulgent Genetics does not have a long track record of dividend growth.

  • News Sentiment

    Fulgent Genetics has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Fulgent Genetics this week, compared to 3 articles on an average week.
  • Search Interest

    5 people have searched for FLGT on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $117,156.00 in company stock.

  • Percentage Held by Insiders

    36.18% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fulgent Genetics' insider trading history.
Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FLGT Stock News Headlines

Office desk with a monitor displaying video, audio, and facial recognition data analysis alongside a lit Veritone logo on the wall.
Think Outside the Box With These 3 Companies That Make Unusual Business Models Work
Fulgent Genetics, Joby Aviation, and Veritone pursue unconventional business models in genomics, eVTOL aircraft, and AI media, backed by notable financial and operational milestones.
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics (FLGT) Q2 2026 Earnings
See More Headlines

FLGT Stock Analysis - Frequently Asked Questions

Fulgent Genetics' stock was trading at $26.27 on January 1st, 2026. Since then, FLGT stock has decreased by 18.2% and is now trading at $21.48.

Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its quarterly earnings data on Thursday, July, 30th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.12. The business had revenue of $85.39 million for the quarter, compared to analyst estimates of $94 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 4.93% and a negative net margin of 26.05%.
Read the conference call transcript
.

The following companies are subsidiaries of Fulgent Genetics: Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC.

Fulgent Genetics (FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Meta Platforms (META), Advanced Micro Devices (AMD), PayPal (PYPL), Broadcom (AVGO) and Arista Networks (ANET).

Company Calendar

Last Earnings
7/30/2026
Today
10/04/2026
Next Earnings (Estimated)
11/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:FLGT
CIK
1674930
Employees
1,315
Year Founded
2011

Price Target and Rating

High Price Target
$36.00
Low Price Target
$19.00
Potential Upside/Downside
+28.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.51 million
Net Margins
-26.05%
Pretax Margin
-28.54%
Return on Equity
-4.93%
Return on Assets
-4.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.34
Quick Ratio
6.34

Sales & Book Value

Annual Sales
$323.93 million
Price / Sales
1.82
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$35.80 per share
Price / Book
0.60

Miscellaneous

Outstanding Shares
27,515,000
Free Float
17,560,000
Market Cap
$591.02 million
Optionable
Optionable
Beta
0.93

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:FLGT) was last updated on 10/4/2026 by MarketBeat.com Staff.
From Our Partners